

References

I-221

1. Hayes, Inc. Hayes Emerging Technology Report. Sarclisa (isatuximab-irfc). Lansdale, PA: Hayes, Inc.; March, 2020.
2. Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicenter, open-label, phase 3 study. *The Lancet*. 2019;394(10214):2096-2107.
3. Mikhael J, Richardson P, Usmani SZ, et al. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. *Blood*. 2019;134(2):123-133.
4. Richardson PG, Attal M, Campana F, et al. Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA phase III study design. *Future Oncology*. 2018;14(11):1035-1047.
5. National Comprehensive Cancer Network (NCCN). Isatuximab. NCCN Drugs and Biologics Compendium®. 2020.
6. Sarclisa (isatuximab-irfc) injection, for intravenous use [package insert]. Sanofi-Aventis U.S., LLC. Bridgewater, NJ. Revised 03/2020.
7. Micromedex®Solutions Compendia. 2020. Isatuximab-irfc.